// App-Quantinova.ai

3254 : Discovery of histone demethylase KDM5C inactivation as a novel mechanism for tumors resistant to VEGF RTKi via genome-wide in-vivo RNAi

Researchers

Presenter

  • Azadeh Fahim Golestaneh

Principal Investigators

  • Maoyun Sun

  • Christian Schwager

  • Zili Tang

  • Stephan Macher-Goeppinger

  • Lila Ma

  • Philip Hahnfeldt

  • Mahmoud Moustafa

  • Wilko Weichert

  • Sascha Pahernik

  • Carsten Grullich

  • Wilfried Roth

  • Jurgen Debus

  • Lynn Hlatky

  • Amir Abdollahi

Medical Centers

  • German Cancer Consortium (DKTK), Molecular- and Translational Radiation Oncology, Heidelberg Ion-beam Therapy Center (HIT), Heidelberg Institute of Radiation Oncology (HIRO), National Center for Tumor Diseases (NCT), Heidelberg University Medical School a, Heidelberg, Germany

  • Center of Cancer Systems Biology, Tufts University School of Medicine, Boston, MA

  • Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

  • Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany

  • Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 31

  • Proliferation marker protein Ki-67

  • Hepatocyte growth factor receptor

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Sunitinib

  • L-Tyrosine

  • TOP-5

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved